Introgen files applications for approval of new cancer therapy
Simultaneously, Gendux Molecular, an Introgen subsidiary, submitted a marketing authorization application to the European Medicines Evaluation Agency for the same indication. Advexin reportedly represents the first of a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.